Evidence map›Paper›PMID 41948173›Full record

ReviewInternational journal of nanomedicine2026

Research Progress of Nanodelivery Platforms in the Diagnosis and Treatment of Esophageal Cancer.

Shuaiqi Sun, Haoyang Huang, Haoxiang Hong, Wenlong Lu, Li Qiu, Shaowei Liu, Sihe Huang, Kaiwen Ye, Jian Sun, Gengliang Lai and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shuaiqi Sun *Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People's Republic of China.ORCID 0009-0002-2572-1376
Haoyang Huang *Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People's Republic of China.
Haoxiang Hong *Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People's Republic of China.ORCID 0009-0003-1877-9825
Wenlong Lu *Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People's Republic of China.
Li QiuDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People's Republic of China.
Shaowei LiuDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People's Republic of China.
Sihe HuangDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People's Republic of China.
Kaiwen YeDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People's Republic of China.
Jian SunDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People's Republic of China.
Gengliang LaiDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People's Republic of China.
Jun LiuDepartment of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal cancer treatment has long been limited by the toxicity of radiotherapy and chemotherapy, multidrug resistance, and low immune response. Nanotechnology, with its precise targeting advantages, offers a new solution. This article reviews its core advances: first, achieving enhanced efficacy and reduced toxicity of radiotherapy and chemotherapy, and reversing drug resistance; second, empowering photodynamic, gene, and immunotherapies, utilizing co-delivery strategies to reshape the microenvironment to activate "cold tumors"; and third, constructing a visualized integrated diagnostic and therapeutic platform. Although clinical translation still faces challenges related to biological barriers and mass production, the integration of biomimetic design, intelligent response, green manufacturing, and organoid screening technologies holds promise for bridging the translational gap and significantly improving patient prognosis.

Indexed as

Drug Delivery SystemsEsophageal NeoplasmsNanomedicineAnimalsAntineoplastic AgentsHumansImmunotherapyNanotechnologyAntineoplastic Agentsclinical translationimmunotherapymultidrug resistancenanodelivery systemtherapeutic integration

Identifiers

PMID41948173
PMCPMC13051193

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.